These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 10929073)

  • 1. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL; Spiller OB; Morgan BP
    Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
    Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
    Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo.
    Harris CL; Williams AS; Linton SM; Morgan BP
    Clin Exp Immunol; 2002 Aug; 129(2):198-207. PubMed ID: 12165074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of double transfection to xenoendothelial cells using both decay accelerating factor and homologous restriction factor 20 genes on complement dependent cytolysis.
    Hayashi S; Emi N; Isobe K; Yokoyama I; Okada H; Takagi H
    J Surg Res; 1996 Feb; 61(1):165-9. PubMed ID: 8769961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
    Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
    Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
    Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
    Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue distribution of the rat analogue of decay-accelerating factor.
    Spiller OB; Hanna SM; Morgan BP
    Immunology; 1999 Jul; 97(3):374-84. PubMed ID: 10447757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4195-202. PubMed ID: 11095615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.
    Song H; He C; Knaak C; Guthridge JM; Holers VM; Tomlinson S
    J Clin Invest; 2003 Jun; 111(12):1875-85. PubMed ID: 12813023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement.
    Hanna S; Spiller O; Linton SM; Mead RJ; Morgan B
    Eur J Immunol; 2002 Feb; 32(2):502-9. PubMed ID: 11828367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
    Qian YM; Haino M; Kelly K; Song WC
    Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.